1. Home
  2. KNSA

KNSA

Kiniksa Pharmaceuticals Ltd.

Logo Kiniksa Pharmaceuticals Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Founded: 2015 Country:
Bermuda
Bermuda
Employees: N/A City: HAMILTON
Market Cap: 1.3B IPO Year: 2018
Target Price: $28.50 AVG Volume (30 days): 356.8K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.20 EPS Growth: -92.31
52 Week Low/High: $10.65 - $22.09 Next Earning Date: 04-30-2024
Revenue: $270,259,000 Revenue Growth: 22.74%
Revenue Growth (this year): 44.52% Revenue Growth (next year): 33.81%

Share on Social Networks: